T he prevalence of neurodevelopmental disorders, like attention-deficit/hyperactivity disorder (ADHD), has been increasing. IMPORTANCE Animal evidence suggests that endocrine disruptors affect germline cells and neurodevelopment. However, to date, the third-generation neurodevelopmental outcomes in humans have not been examined.
Despite compelling evidence from toxicological studies, epidemiological evidence in humans of EDC-associated multigenerational neurodevelopmental outcomes is currently unavailable, likely because of the lack of large cohorts with relevant information across multiple generations.
In this study, we used data from the Nurses' Health Study II (NHSII) to examine the potential third-generation outcomes (ADHD) of diethylstilbestrol, a potent perinatal EDC. Between 1938 and 1971, diethylstilbestrol was given to pregnant women to prevent pregnancy complications. The exact number of women worldwide who used diethylstilbestrol is unknown, but between 5 and 10 million women in the United States were estimated to have used it. 29 Prescription of the drug started to phase out after a 1953 study found diethylstilbestrol had no actual treatment value, 30 and it was banned in 1971 after another study linked it to vaginal adenocarcinomas in female children of the women who used diethylstilbestrol. 31 Later, it was found to be associated with multiple other reproductive adverse outcomes in female offspring. 29 Only a few studies have considered EDCs and their outcomes for the third generation. For example, exposure to diethylstilbestrol during pregnancy was linked to hypospadias in the grandsons [32] [33] [34] and to delayed menstrual regularization in the granddaughters 35 of the exposed women. To our knowledge, no epidemiological study to date has assessed the multigenerational neurodevelopmental consequences of diethylstilbestrol or any other EDCs.
Methods

Data Collection Study Population
In 1989, a total of 116 686 female registered nurses between the ages of 25 and 42 years enrolled in the NHSII prospective cohort by completing a mailed questionnaire. At baseline, participants resided in 14 US states (California, Connecticut, Indiana, Iowa, Kentucky, Massachusetts, Michigan, Mississippi, New York, North Carolina, Ohio, Pennsylvania, South Carolina, and Texas), but they have since moved to all 50 states. The NHSII has a retention rate of more than 90%. Follow-up questionnaires are mailed to participants every 2 years to gather updated information on lifestyle and risk factors, medication use, and major illness occurrence. Our study was approved by the institutional review board of Brigham and Women's Hospital, Boston, Massachusetts, and the human subjects committee of Harvard T. H. Chan School of Public Health, Boston. Participants provided implied informed consent by completing and returning the questionnaire. All NHSII participants (F1 generation) were born between 1946 and 1964, when diethylstilbestrol was still being prescribed. In 1993, the mailed questionnaire included questions about the use of diethylstilbestrol by the participant's mother (F0 generation) during her pregnancy with the F1 participant. We excluded from our analyses F1 participants who did not return the 1993, 2005, or 2013 questionnaires (the relevant surveys that collected outcome and exposure data) and who did not report any live-born children. Because children (F2 generation) with ADHD were identified only by their year of birth, we also excluded F1 participants with multiple pregnancies (eg, twins, triplets) and same-year births (from different pregnancies), as matching the response to the appropriate child born in the same year would not be possible. The final data set for the main analysis included 47 540 F0 mothers as well as 106 198 live-born F2 children.
Exposure Assessment
In 1993, a supplementary questionnaire was mailed to 2742 F1 participants who reported that their F0 mothers had been exposed to diethylstilbestrol while pregnant with the F1 participants. Among the 2317 participants (84.5%) who responded, 2032 (87.7%) reported being certain or somewhat certain of their mothers' exposure, 123 (5.3%) were not certain, and 162 (7.0%) reported no such exposure. Thus, we considered only those who were certain or somewhat certain of their mothers' exposure, excluding those who were not certain or had originally said yes but later reported no exposure. The 1993 questionnaire also included questions on trimester-specific diethylstilbestrol use-that is, any exposure during the first, second, or third trimester of pregnancy.
In 2001, a total of 29 070 F0 mothers received a questionnaire pertaining to their pregnancy with the F1 participants; it included a question about diethylstilbestrol use. We observed very good agreement between the mothers' responses to the 2001 survey and prior reports by the F1 in 1993 (κ = 0.74) 36 ,37 that did not vary by ADHD status.
Outcome Assessment
The outcome of interest was an F1 participant's report of whether any of her children ever received a doctor's diagnosis of ADHD. This question was first asked in the 2005 questionnaire, although at that time the date of birth of the child or children with ADHD was not asked. This question was repeated in the 2013 questionnaire, further requesting information on the birth years of the children with an ADHD physician diagnosis. Maternal reports of ADHD have been found to be reliable. 38 Moreover, in a validation study involving 92 F1 participants who reported in the 2005 questionnaire of having a child diagnosed with ADHD, we found that the F2 children scored high on the ADHD Rating Scale-IV. 39 All girls scored above 90%, 81.1% of boys scored above 80%, and 63.8% of boys scored above 90%.
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Key Points
Question Is exposure to diethylstilbestrol during pregnancy associated with adverse multigenerational neurodevelopmental outcomes?
Findings A cohort study of 47 450 women in the Nurses' Health Study II found significantly elevated odds for attention-deficit/ hyperactivity disorder in the grandchildren (third generation) of users of diethylstilbestrol, a potent endocrine disruptor.
Meaning Exposure to endocrine disruptors during pregnancy may be associated with multigenerational neurodevelopmental deficits.
For our main analysis, we included information on F1 participants who provided concordant responses (92.6% concordance) in the 2005 and 2013 questionnaires to the question of whether any of their children had been diagnosed with ADHD by a physician, using the child-specific responses from the 2013 questionnaire to minimize any potential outcome misclassification. We also conducted analyses of all participants who responded to the 2013 questionnaire to include their children, who may have received a diagnosis after 2005.
Covariates
Potential confounders of the association between F0 mothers' diethylstilbestrol exposure and F2 children's ADHD could only be variables that preceded diethylstilbestrol exposure 41 (ie, F0 mother-level variables). Therefore, we did not consider participant or child variables as covariates in the health models except for self-identified participant race/ethnicity, which was assumed to reflect the mother's race/ethnicity. In the 1999 questionnaire, participants were asked whether their mothers smoked during pregnancy. In the 2005 questionnaire, participants were asked about their family socioeconomic status at their birth as well as their mother's lifestyle, educational level, and occupation. We adjusted for the participant's race (white, African American, Asian, or other), ethnicity (Hispanic-yes or no), and year of birth (and squared year of birth to account for nonlinear confounding); mother's smoking during pregnancy (yes or no); mother's home ownership at the time of pregnancy (yes or no); mother's education (<9 years, 1-3 years of high school, 4 years of high school, 1-3 years of college, or ≥4 years of college); father's educational level (same categories); mother's occupation (professional, executive/manager, sales/clerical work, mechanic/ skilled, machine operator/driver, service worker, laborer/ unskilled work, farming, military, or housekeeping); and father's occupation (same categories).
Because of previous reports of an association between F0 mother's diethylstilbestrol exposure and F1 participant's depression 37 as well as between depression and ADHD, 42 in a sensitivity analysis we adjusted for the mother's depression history, which was reported by the participants in the 2005 survey. However, this sensitivity analysis was only a secondary analysis, as information was not available on the timing of the diagnosis of the mother's depression relative to her index pregnancy. In a secondary analysis, we adjusted for the mother's age when the participant was born because age at delivery was unknown for 1928 F0 mothers (4.1%) in our study. We included a missing indicator for other covariates with missing responses, which arose mostly when the participant did not know the response for her mother.
Statistical Analysis Data Analysis
In utero exposure to diethylstilbestrol is known to affect women's reproductive ability, which could affect the number of grandchildren within the F0 generation and the likelihood that any F2 child has ADHD-that is, the distribution of ADHD given diethylstilbestrol potentially may depend on the number of children within the F1 generation-for which our data provide evidence (results not shown). This structure is defined as informative clustering. [43] [44] [45] Standard generalized estimating equation approaches are not appropriate for this analysis and would result in invalid estimates and inferences. [43] [44] [45] We used cluster-weighted generalized estimating equations with a logit link to account for multiple children within the F1 generation, adjusting for potential confounders with the inverse of the cluster size (ie, number of children per participant) as the weights to account for informative clustering. 45 We also assessed potential effect modification by F2 children's sex by including in the model an interaction term between F0 mothers' diethylstilbestrol use and F2 children's sex. We considered any diethylstilbestrol exposure during pregnancy and trimester-specific exposures. These exposures were not mutually exclusive and were modeled as 3 binary variables along with another variable for those who did not know about trimester-specific timing; all were included simultaneously in 1 model. Results were similar when we repeated this analysis using separate models for each trimester and excluding the 302 F0 mothers (with 625 F2 children) who did not know the trimester of exposure.
Our results are reported as odds ratios (ORs) and 95% CIs. Statistical significance was assessed at α = .05; all P values presented are for 2-tailed tests. All analyses were conducted using SAS statistical software, version 9.4 (SAS Institute Inc).
Sensitivity Analyses
As stated, we repeated the analyses using the ADHD-related responses to only the 2013 questionnaire. In addition, we conducted sensitivity analyses to assess the outcome of potential unmeasured confounding by calculating the E valuethat is, the minimal strength at which a confounder would need to be associated with both the outcome and the exposure of interest to fully explain the observed association. 46 
Results
In the main analysis, we included information on 47 540 F0 mothers, 861 (1.8%) of whom were exposed to diethylstilbestrol while pregnant with the F1 participants and 46 679 (98.2%) who were not. Table 1 presents descriptive characteristics of the mothers and participants by diethylstilbestrol use. The F1 participants had a median of 2 children (range, 1-12) if their F0 mothers did not use diethylstilbestrol while pregnant and a median of 2 children (range, 1-5) if their mothers used diethylstilbestrol. Table 2 presents descriptive characteristics of the F1 participants and their F0 mothers by the ADHD status of the F2 children. The total number of children was 106 198, and 5587 (5.3%) of them were diagnosed with ADHD. The median F2 year of birth was 1983 (interquartile range, 1978-1988). The grandmothers of 137 F2 children with ADHD (2.5%) were exposed to diethylstilbestrol while pregnant with the F1 participants.
We observed harmful associations between the F0 mothers' diethylstilbestrol use while pregnant and the F2 child's ADHD diagnosis ( Table 3) . Use of diethylstilbestrol by F0 mothers was associated with increased odds of ADHD among the F2 generation (adjusted OR, 1.36; 95% CI, 1.10-1.67).
Further adjusting for F0 mothers' age at delivery (excluding 1928 F0 mothers and 4368 F2 children with unknown age) yielded the same results (OR, 1.35; 95% CI, 1.09-1.66; P = .005). We observed no difference in the effect estimate when we included information on F0 mothers' depression history in the main model (OR, 1.33; 95% CI, 1.08-1.63; P = .007).
Information on sex was available for only 100 786 F2 children, 48 831 (48.5%) of whom were female. Of the 5338 F2 children with ADHD who had available sex information, 3977 (74.5%) were male. We found no effect modification by children's sex (P = .62 for the interaction).
In the trimester-specific analysis, we observed that the association was limited to diethylstilbestrol use during the first trimester (OR, 1.63; 95% CI, 1.18-2.25). The ORs for the other trimesters were not substantially different from 1 (Table 3) .
In sensitivity analyses, among the 51 561 F0 mothers and 115 806 F2 children (8699 [7.5%] of whom had ADHD) identified when only the ADHD reported on the 2013 questionnaire was considered, we found an OR of 1.28 (95% CI, 1.08-1.52; P = .005) for any diethylstilbestrol use during pregnancy. Our sensitivity analyses of potential unmeasured confounding are presented in the eMethods and eFigure in the Supplement. Briefly, we do not believe that the estimated associations can be fully attributed to unmeasured confounding.
Discussion
We conducted a large-scale cohort analysis to assess the association between use of diethylstilbestrol during pregnancy and third-generation ADHD. The observed associations were robust to covariate adjustment and sensitivity analyses. Despite animal evidence of adverse multigenerational consequences-including neurodevelopmental disorders-of EDC exposure, 27,28,47 to date only a few studies have explored the potential multigenerational implications of EDC exposure in humans. These studies have only considered diethylstilbestrol exposure, and none has studied neurodevelopmental outcomes. Some studies have reported increased risk of hypospadias in grandsons of women exposed to diethylstilbestrol Oocytes that will develop into the F2 child grow while the F1 mother is still in utero. Thus, third-generation implications of diethylstilbestrol (and other EDC) exposures could relate to direct exposure of F1's oocytes developing during the F0 pregnancy. This does not imply transgenerational inheritance of epigenetic changes (ie, effects that do not derive from direct exposures, which would require F3 assessment), but animal studies do suggest that epigenetics play a role. Evidence from animal studies suggests that the biological pathway for multigenerational and transgenerational consequences of EDCs involves molecular alterations to the germline, mediated through epigenetic mechanisms, to promote outcomes to subsequent generations [22] [23] [24] [25] [26] ; this process is known as epigenetic transgenerational inheritance. 22, 49 As described earlier, F0 exposure to EDCs-specifically to di(2-ethylhexyl) phthalate and bisphenol A-has been linked to behavioral changes and altered social interactions among mice in later generations.
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Direct epidemiological evidence of multigenerational and transgenerational neurodevelopmental outcomes of EDCs is lacking, but 2 studies have reported increased risk for ADHD and autism spectrum disorders among boys with hypospadias, 50, 51 which in F2 has also been linked to F0 diethylstilbestrol exposure during pregnancy. 34 Note that diethylstilbestrol is similar structurally and functionally to bisphenol A, albeit more potent. 52 However, Newbold et al 47 have
observed multigenerational consequences of diethylstilbestrol even at very low diethylstilbestrol estrogenic doses comparable to environmental EDC exposures. Our trimester-specific analyses indicated that firsttrimester F0-generation diethylstilbestrol use is associated with significantly increased risk for F2-generation ADHD. The associations with diethylstilbestrol use during the second and third trimesters were slightly weaker and not significant. The a F1 father's occupation categories are not mutually exclusive.
Research Original Investigation
Exposure to Diethylstilbestrol During Pregnancy and Multigenerational Neurodevelopmental Deficits attenuated associations with the other trimesters could result from the smaller number of exposed cases (33 for the second trimester and 27 for the third trimester vs 82 for the first trimester). Although additional studies are warranted, these findings could suggest that the first trimester is a critical exposure window. The early phase of gestation is thought to be especially sensitive to maternal influences, resulting in embryonic and germ cell reprogramming, because during this period a wave of genome demethylation followed by de novo remethylation occurs together with the establishment of imprints and determination of sex.
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Limitations
We were in the unique position to access information across 3 generations in a well-defined nationwide cohort comprising a large number of F2-generation ADHD cases and extensive follow-up. Our findings, nevertheless, should be interpreted in light of our limitations. Outcome misclassification is possible. The ADHD assessment was based on maternal reports of a doctor's diagnosis. Maternal reports have been found to be highly reliable, 38 and we found good agreement in the internal validation study. In addition, in a sensitivity analysis including all 2013 questionnaire responses, we observed only a slight attenuation, suggesting that any bias from misclassification was likely minimal.
Some exposure misclassification is likely, as exposure assessment depended on the F1 participants' report on whether their F0 mothers used diethylstilbestrol. To minimize potential exposure misclassification, we excluded from our analyses any women whose exposure was uncertain. Furthermore, the small validation study in our data comparing F1 responses with those directly obtained from F0 mothers showed very good agreement. Any exposure or outcome misclassification is likely nondifferential, as information on exposure was collected 12 to 20 years prior to the question about the outcome and in 1993 (when the question on diethylstilbestrol use was asked) there was no toxicological or epidemiological evidence of EDC multigenerational outcomes. Indeed, in our validation study, we found that agreement between F0-generation and F1-generation diethylstilbestrol reporting did not vary by ADHD status. Any potential resulting bias, thus, would likely be toward the null.
Some residual confounding is possible given that we used F1-provided information on F0 factors. However, we included information about several socioeconomic status factors, including smoking during pregnancy, and conducted sensitivity analyses; therefore, our findings are not likely to be completely attributable to residual confounding. Finally, although confounding by indication is possible, the observed different consequences across trimester-specific diethylstilbestrol use suggest that this is unlikely.
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Conclusions
We found evidence in humans of increased ADHD risk in the third generation following diethylstilbestrol exposure during F0 pregnancy. The levels of a high number of EDCs to which humans are daily exposed are lower than that of the prescribed diethylstilbestrol; thus, extending this work to lower levels of exposure is warranted. Because EDCs are ubiquitous, the high prevalence of exposure and the possibility of cumulative consequences must be considered. 
ARTICLE INFORMATION
eMethods. Impact of Unmeasured Confounding
We have conducted further sensitivity analyses to assess the sensitivity of our results to residual and unmeasured confounding. First, we estimated the E-value, i.e. how strongly (the minimal strength) a confounder would need to be related both to the exposure and outcome of interest to fully explain the observed association. We used the method as described in VanderWeele and Ding 1 and the online calculator provided by the authors (https://www.hsph.harvard.edu/tylervanderweele/tools-and-tutorials/). For an odds ratio (OR) of 1.36 of a rare event (outcome prevalence <15%), the E-value estimated was 2.06 (see the eFigure). However, since there are no other existing studies assessing multigenerational neurodevelopmental effects of DES, we cannot assess if it is reasonable to expect that such a confounder exists that we have not considered.
When looking at the results from our main models, the strongest positive association observed with ADHD was with F1 year of birth ( = 0.84; OR = 2.32) and the strongest negative associations were with race (Asian = -0.98; OR = 0.38, and African American = -0.62; OR = 0.54). The next strongest association in absolute magnitude in our model was with DES ( = 0.31; OR = 1.36). We subsequently proceeded to remove each of the potential confounders from the model, one at a time, to assess the impact each of these variables has on the estimated coefficient for DES. The range of the resulting ORs was very tight, i.e. the estimated ORs ranged between 1.35 and 1.38. Removing the two strongest predictors for ADHD (F1 birth year and race) resulted in ORs of 1.36 and 1.37, respectively, indicating that they are not strong confounders. The highest difference (OR = 1.38, i.e. a 4.2% increase in the coefficient compared to the main analysis) was when we removed F0 smoking during pregnancy from the model.
Although we cannot exclude the possibility of some residual or unmeasured confounding, we included information about several SES-related factors, including smoking during pregnancy. This, combined with the sensitivity analyses described above, indicates that it is not likely that our findings could be completely attributable to residual or unmeasured confounding.
